{"title":"血浆动脉粥样硬化指数累积暴露与心脏代谢疾病风险之间的关系：一项前瞻性队列研究","authors":"Meixiao Wang, Shihe Liu, Luqing Liu, Xinran Wen, Yicheng Liao, Hongmin Liu, Shouling Wu, Yuntao Wu","doi":"10.1007/s12020-025-04197-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Plasma atherogenic index is a major risk factor for cardiac metabolic disease, but the long-term effect of high cumAIP on the risk of CMD development is unclear. Therefore, we aimed to determine the effect of cumulative plasma atherogenic index exposure on cardiac metabolic disease.</p><p><strong>Methods: </strong>A total of 44,603 subjects who participated in the Kailuan Study health examination in 2006, 2008 and 2010, had complete blood lipid data, and had no previous history of CMD or cancer were selected. The cumulative AIP index was calculated as a weighted sum (value × time) of the average AIP index during each time interval. The population was divided into four groups according to the cumAIP quartile level. Cox proportional hazards regression model and restricted cubic spline regression model were used to further analyze the effect of cumAIP on the risk of CMD. Due to the competing risk of death, the traditional Cox model may cause bias on the risk of CMD. Therefore, death was regarded as a competing event, and the Fine-Gray model was used to analyze the difference in the risk of CMD in different cumAIP groups.</p><p><strong>Results: </strong>During a mean follow-up period of (9.79 ± 2.60) years, 7674 (17.21%) of 44603 participants developed CMD. After adjusting for potential confounding factors, Cox regression analysis showed that compared with group Q1, the risk of CMD in group Q2, Q3, and Q4 increased by 26% (HR = 1.26, 95%CI: 1.17-1.36) and 44% (HR = 1.44, 95%CI: 1.17-1.36), respectively. 95%CI: 1.34-1.55), 83% (HR = 1.83, 95%CI: 1.70-1.96). Each standard deviation increase in the risk of myocardial infarction, revascularization, ischemic stroke, and type 2 diabetes was 1.25 (1.15, 1.36), 1.19 (1.12, 1.26), 1.08 (1.03, 1.13), and 1.35 (1.31, 1.39) for cumAIP, respectively.</p><p><strong>Conclusions: </strong>There was a significant association between high levels of cumAIP exposure and higher risk of CMD. The effect of long-term exposure to high levels of cumAIP on increasing the risk of CMD was more obvious in the low-risk population.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association between the cumulative exposure to atherogenic index of plasma and risk of cardiometabolic diseases: a prospective cohort study.\",\"authors\":\"Meixiao Wang, Shihe Liu, Luqing Liu, Xinran Wen, Yicheng Liao, Hongmin Liu, Shouling Wu, Yuntao Wu\",\"doi\":\"10.1007/s12020-025-04197-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Plasma atherogenic index is a major risk factor for cardiac metabolic disease, but the long-term effect of high cumAIP on the risk of CMD development is unclear. Therefore, we aimed to determine the effect of cumulative plasma atherogenic index exposure on cardiac metabolic disease.</p><p><strong>Methods: </strong>A total of 44,603 subjects who participated in the Kailuan Study health examination in 2006, 2008 and 2010, had complete blood lipid data, and had no previous history of CMD or cancer were selected. The cumulative AIP index was calculated as a weighted sum (value × time) of the average AIP index during each time interval. The population was divided into four groups according to the cumAIP quartile level. Cox proportional hazards regression model and restricted cubic spline regression model were used to further analyze the effect of cumAIP on the risk of CMD. Due to the competing risk of death, the traditional Cox model may cause bias on the risk of CMD. Therefore, death was regarded as a competing event, and the Fine-Gray model was used to analyze the difference in the risk of CMD in different cumAIP groups.</p><p><strong>Results: </strong>During a mean follow-up period of (9.79 ± 2.60) years, 7674 (17.21%) of 44603 participants developed CMD. After adjusting for potential confounding factors, Cox regression analysis showed that compared with group Q1, the risk of CMD in group Q2, Q3, and Q4 increased by 26% (HR = 1.26, 95%CI: 1.17-1.36) and 44% (HR = 1.44, 95%CI: 1.17-1.36), respectively. 95%CI: 1.34-1.55), 83% (HR = 1.83, 95%CI: 1.70-1.96). Each standard deviation increase in the risk of myocardial infarction, revascularization, ischemic stroke, and type 2 diabetes was 1.25 (1.15, 1.36), 1.19 (1.12, 1.26), 1.08 (1.03, 1.13), and 1.35 (1.31, 1.39) for cumAIP, respectively.</p><p><strong>Conclusions: </strong>There was a significant association between high levels of cumAIP exposure and higher risk of CMD. The effect of long-term exposure to high levels of cumAIP on increasing the risk of CMD was more obvious in the low-risk population.</p>\",\"PeriodicalId\":11572,\"journal\":{\"name\":\"Endocrine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12020-025-04197-9\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-025-04197-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Association between the cumulative exposure to atherogenic index of plasma and risk of cardiometabolic diseases: a prospective cohort study.
Purpose: Plasma atherogenic index is a major risk factor for cardiac metabolic disease, but the long-term effect of high cumAIP on the risk of CMD development is unclear. Therefore, we aimed to determine the effect of cumulative plasma atherogenic index exposure on cardiac metabolic disease.
Methods: A total of 44,603 subjects who participated in the Kailuan Study health examination in 2006, 2008 and 2010, had complete blood lipid data, and had no previous history of CMD or cancer were selected. The cumulative AIP index was calculated as a weighted sum (value × time) of the average AIP index during each time interval. The population was divided into four groups according to the cumAIP quartile level. Cox proportional hazards regression model and restricted cubic spline regression model were used to further analyze the effect of cumAIP on the risk of CMD. Due to the competing risk of death, the traditional Cox model may cause bias on the risk of CMD. Therefore, death was regarded as a competing event, and the Fine-Gray model was used to analyze the difference in the risk of CMD in different cumAIP groups.
Results: During a mean follow-up period of (9.79 ± 2.60) years, 7674 (17.21%) of 44603 participants developed CMD. After adjusting for potential confounding factors, Cox regression analysis showed that compared with group Q1, the risk of CMD in group Q2, Q3, and Q4 increased by 26% (HR = 1.26, 95%CI: 1.17-1.36) and 44% (HR = 1.44, 95%CI: 1.17-1.36), respectively. 95%CI: 1.34-1.55), 83% (HR = 1.83, 95%CI: 1.70-1.96). Each standard deviation increase in the risk of myocardial infarction, revascularization, ischemic stroke, and type 2 diabetes was 1.25 (1.15, 1.36), 1.19 (1.12, 1.26), 1.08 (1.03, 1.13), and 1.35 (1.31, 1.39) for cumAIP, respectively.
Conclusions: There was a significant association between high levels of cumAIP exposure and higher risk of CMD. The effect of long-term exposure to high levels of cumAIP on increasing the risk of CMD was more obvious in the low-risk population.
期刊介绍：
Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology.
Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted.
Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
